We provide you with 20 years of free, institutional-grade data for BGNE stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of BGNE. Explore the full financial landscape of BGNE stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Wu Xiaobin | Grant, award...etc | 123,370 | 2025-06-12 | ||
| OYLER JOHN | Grant, award...etc | 185,055 | 2025-06-12 | ||
| Wang Xiaodong | Grant, award...etc | 98,696 | 2025-06-12 | ||
| Rosenberg Aaron | Grant, award...etc | 63,674 | 2025-06-12 | ||
| Wang Lai | Grant, award...etc | 86,359 | 2025-06-12 | ||
| Lee Chan Henry | Grant, award...etc | 46,878 | 2025-06-12 | ||
| Ball Titus B. | Grant, award...etc | 29,601 | 2025-06-12 | ||
| Yi Qingqing | Grant, award...etc | 10,985 | 2025-05-23 | ||
| BAKER BROS. ADVISORS LP | Grant, award...etc | 21,970 | 2025-05-22 | ||
| BAKER BROS. ADVISORS LP | Grant, award...etc | 21,970 | 2025-05-22 | ||
| HOOPER ANTHONY C | Grant, award...etc | 10,985 | 2025-05-22 | ||
| Dugan Margaret | Grant, award...etc | 10,985 | 2025-05-22 | ||
| Sanders Corazon (Corsee) D. | Grant, award...etc | 10,985 | 2025-05-22 | ||
| Sharp Shalini | Grant, award...etc | 10,985 | 2025-05-22 | ||
| Riva Alessandro | Grant, award...etc | 10,985 | 2025-05-22 | ||
| BRANDICOURT OLIVIER | Grant, award...etc | 10,985 | 2025-05-22 | ||
| OYLER JOHN | Sale | -1,990,603 | $17.85 | $35,532,264 | 2025-05-13 |
| OYLER JOHN | Derivatives Exercise | 4,055,415 | 2025-05-13 | ||
| OYLER JOHN | Derivatives Exercise | 497,822 | 2025-03-12 | ||
| OYLER JOHN | Grant, award...etc | 201,084 | 2025-03-07 | ||
| OYLER JOHN | Derivatives Exercise | 1,194,908 | 2025-03-07 | ||
| Wu Xiaobin | Grant, award...etc | 103,883 | 2025-03-07 | ||
| Wang Lai | Grant, award...etc | 69,251 | 2025-03-07 | ||
| Lee Chan Henry | Grant, award...etc | 40,209 | 2025-03-07 | ||
| Rosenberg Aaron | Grant, award...etc | 48,581 | 2025-03-07 | ||
| OYLER JOHN | Derivatives Exercise | 1,220,531 | 2025-03-05 | ||
| OYLER JOHN | Derivatives Exercise | 1,300,000 | 2024-12-17 | ||
| HHLR ADVISORS, LTD. | Sale | -17,842,500 | $200 | $3,568,500,000 | 2024-12-04 |
| Sharp Shalini | Grant, award...etc | 8,151 | 2024-10-02 |
The information provided in this report about BGNE stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
BeiGene, Ltd(NASDAQ:BGNE) 
BeiGene, Ltd., a commercial-stage biotechnology company, engages in discovering, developing, manufacturing, and commercializing medicines for cancer therapeutics in the People's Republic of China and the United States. Its commercial products include BRUKINSA to treat relapsed/refractory (R/R) mantl...
Website: http://www.beigene.com
Founded: 2010
Full Time Employees: 9,400 (Dec 2022)
Sector: Healthcare
Industry: Biotechnology